Key result
DUX4 directly activates the expression of FRG2 by binding to its promoter, demonstrating that FSHD-specific upregulation of FRG2 is a direct consequence of DUX4 protein activity.
The study demonstrates that FSHD-specific upregulation of FRG2 is a direct consequence of DUX4 protein activity rather than regional de-repression, reinforcing DUX4's central role in FSHD pathology.
BACKGROUND: The most common form of facioscapulohumeral muscular dystrophy (FSHD) is caused by a genetic contraction of the polymorphic D4Z4 macrosatellite repeat array in the subtelomeric region of chromosome 4q. In some studies, genes centromeric to the D4Z4 repeat array have been reported to be over-expressed in FSHD, including FRG1 and FRG2, presumably due to decreased long-distance repression by the shorter array through a mechanism similar to position-effect variegation. Differential regulation of FRG1 in FSHD has never been unequivocally proven, however, FRG2 has been reproducibly shown to be induced in primary FSHD-derived muscle cells when differentiated in vitro. The molecular function of FRG2 and a possible contribution to FSHD pathology remain unclear. Recent evidence has identified the mis-expression of DUX4, located within the D4Z4 repeat unit, in skeletal muscle as the cause of FSHD. DUX4 is a double homeobox transcription factor that has been shown to be toxic when expressed in muscle cells. METHODS: We used a combination of expression analysis by qRT/PCR and RNA sequencing to determine the transcriptional activation of FRG2 and DUX4. We examined this in both differentiating control and FSHD derived muscle cell cultures or DUX4 transduced control cell lines. Next, we used ChIP-seq analysis and luciferase reporter assays to determine the potential DUX4 transactivation effect on the FRG2 promoter. RESULTS: We show that DUX4 directly activates the expression of FRG2. Increased expression of FRG2 was observed following expression of DUX4 in myoblasts and fibroblasts derived from control individuals. Moreover, we identified DUX4 binding sites at the FRG2 promoter by chromatin immunoprecipitation followed by deep sequencing and confirmed the direct regulation of DUX4 on the FRG2 promoter by luciferase reporter assays. Activation of luciferase was dependent on both DUX4 expression and the presence of the DUX4 DNA binding motifs in the FRG2 promoter. CONCLUSION: We show that the FSHD-specific upregulation of FRG2 is a direct consequence of the activity of DUX4 protein rather than representing a regional de-repression secondary to fewer D4Z4 repeats.
No takes yet. Share an insight, caveat, or question.
Thijssen et al. (2014) studied Facioscapulohumeral muscular dystrophy (n=21). DUX4 expression vs. Control cells or empty vector was evaluated on Transcriptional activation of FRG2. DUX4 directly activates the expression of FRG2 by binding to its promoter, demonstrating that FSHD-specific upregulation of FRG2 is a direct consequence of DUX4 protein activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: